Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2015 5,14 M
EBIT 2015 1,16 M
Net income 2015 1,08 M
Debt 2015 -
Yield 2015 -
Sales 2016 11,6 M
EBIT 2016 6,71 M
Net income 2016 5,98 M
Debt 2016 -
Yield 2016 -
PER 2015 32,33
PER 2016 5,10
Capi. / Sales 2015 6,00x
Capi. / Sales 2016 2,66x
Capitalization 30,9 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
11/11Earnings Release
More about the company
Latest news on INTELGENX TECHNOLOGIES COR
08/12 INTELGENX TECHNOLOGIES : Reports Q2 and First Six Months 2015 Results and Provid..
08/10 INTELGENX TECHNOLOGIES : 2015-08-10 IntelGenx Reports Q2 and First Six Months 20..
08/10 INTELGENX TECHNOLOGIES CORP. : IntelGenx Reports Q2 and First Six Months 2015 Re..
08/10 IntelGenx Reports Q2 and First Six Months 2015 Results and Provides Corporate..
08/10 INTELGENX TECHNOLOGIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
08/10 INTELGENX TECHNOLOGIES : DGAP-News: IntelGenx Reports Q2 and First Six Months 20..
08/10 INTELGENX TECHNOLOGIES : to Provide Second Quarter 2015 Update on August 10, 201..
08/10 INTELGENX TECHNOLOGIES : Announces Appointment of New Director
More news
Sector news : Generic Pharmaceuticals
03:37p PERRIGO : BRIEF: Mylan shareholders approve Perrigo takeover bid
03:35pDJFDA Says Certain Type 2 Diabetes Drugs Can Cause Serious Joint Pain -- Update
03:28pDJBaxalta in Talks to Buy Ariad -Bloomberg
More sector news : Generic Pharmaceuticals
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions